This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Alexandria Real Estate Equities' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Stocks in this article: ARE

Now I would like to turn the call over to Mr. Joel Marcus. Please go ahead.

Joel Marcus

Thanks, Rhonda, and welcome, everybody, to the second quarter conference call. With me today are Dean Shigenaga, Steve Richardson, Peter Moglia, Krupal Raval. I guess I would like to start out with a bit of a macro view for I guess the second quarter which really epitomizes – I think where we see things today from a strategic advantage point. And that is scientific advancement as a team froth that can be best done in a bio-pharma hub with multiple players that’s what Boston is to us.

And this was a quote recently in a interview by Elias Zerhouni he was President of the Global Research at Sanofi and as many of you know he was former head of the NIH, who really pioneered translational research in areas best positioned to take maximum advantage of this. I’d kind of like to label the macro industry comments today, what I’d call the gathering pipeline momentum. We’re witnessing a perfect explosion of biotech products, earnings and expansion, really what I call the biotech business. And just to name a few companies that are participating, many of which are our clients, Amgen, Celgene, Biogen Idec, Gilead, Alexion, Vertex, and Onyx.

If you look at the markets, the Supreme Court’s confirmation that the constitutionality of essentially Obamacare will move U.S. to full coverage of over 300 million people, which means the market, will be increasing and clearly the increasing of the emerging markets is – where big pharma is heavily focused as well. Last year, the U.S. spent $320 billion on medicine, so there certainly is a robust business.

Today’s climate is actually a lot better than you might think the FDA’s been doing over the last year or two, a much better job, I think from the industry perspective, a job of – approval of new medicines. And if you look at through today 7/31/ 2012, 18 drugs have been approved and an amazing 50% of which were ARE client tenants. The PDUFA law that was just enacted, included some very important helpful attributes for the biotech and the pharma industry, including confirmation of 12-year data exclusivity, fast track approval for new noble drugs which we were involved with and I think it’s also fair to say that based on what we hear from Washington, it appear that the NIH will be spared cuts if we get an election that makes sense here. So, we’re hopeful about that.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs